This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Manor, D. Articles by Noy, N. Search for Related Content PubMed PubMed Citation Articles by Manor, D. Articles by Noy, N.

Mammary Carcinoma Suppression by Cellular Retinoic Acid Binding Protein-II¹

Division of Nutritional Sciences [D. M., A. B., N. N.], Department of Biomedical Sciences [E. N. S., A. F-N., A. Y. N.], and Department of Clinical Sciences [M. Z., R. P.], Cornell University, Ithaca, New York 14853

Retinoic acid (RA) modulates cell proliferation, differentiation, and apoptosis, and is used in chemotherapy and chemoprevention in several human cancers. RA exerts its pleiotropic activities by activating the nuclear receptors, retinoic acid receptor (RAR), which, in turn, regulate transcription of multiple target genes. In cells, RA also associates with cellular RA-binding proteins [cellular RA binding proteins (CRABPs)-I and -II]. Recent studies revealed that CRABP-II functions by "channeling" RA to RAR, thereby enhancing the transcriptional activity of the receptor. In search for a biologically meaningful role for CRABP-II, we examined its effect on RA-induced growth inhibition in RA-resistant tumors. Stable expression of CRABP-II in mammary carcinoma SC115 cells enabled activation of RAR, considerably sensitized the cells to RA-induced growth inhibition, and dramatically suppressed their tumorigenicity in immunodeficient mice. Similarly, injection of an adenovirus expressing CRABP-II into mammary carcinomas that spontaneously develop in TgN(MMTVneu)202Mul mice resulted in a significant delay in tumor growth and in prolonged survival rates. Remarkably, in both mouse models, administration of exogenous RA had no additional beneficial effect, indicating that endogenous levels of RA are sufficient for maximal tumor suppression on CRABP-II overexpression. The observations reveal that CRABP-II plays a critical role in sensitizing tumors to the growth-suppressive activities of RA in vivo.

This article has been cited by other articles:

				T. T. Schug, D. C. Berry, I. A. Toshkov, L. Cheng, A. Y. Nikitin, and N. Noy Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPAR{beta}/{delta} to RAR PNAS, May 27, 2008; 105(21): 7546 - 7551. [Abstract] [Full Text] [PDF]

				A. Flesken-Nikitin, I. Toshkov, J. Naskar, K. M. Tyner, R. M. Williams, W. R. Zipfel, E. P. Giannelis, and A. Yu. Nikitin Toxicity and Biomedical Imaging of Layered Nanohybrids in the Mouse Toxicol Pathol, October 1, 2007; 35(6): 804 - 810. [Abstract] [Full Text] [PDF]

				L. J. Donato, J. H. Suh, and N. Noy Suppression of Mammary Carcinoma Cell Growth by Retinoic Acid: the Cell Cycle Control Gene Btg2 Is a Direct Target for Retinoic Acid Receptor Signaling Cancer Res., January 15, 2007; 67(2): 609 - 615. [Abstract] [Full Text] [PDF]

				A. Gupta, B. R.G. Williams, S. M. Hanash, and J. Rawwas Cellular Retinoic Acid-Binding Protein II Is a Direct Transcriptional Target of MycN in Neuroblastoma Cancer Res., August 15, 2006; 66(16): 8100 - 8108. [Abstract] [Full Text] [PDF]

				J. Ni, X. Wen, J. Yao, H.-C. Chang, Y. Yin, M. Zhang, S. Xie, M. Chen, B. Simons, P. Chang, et al. Tocopherol-Associated Protein Suppresses Prostate Cancer Cell Growth by Inhibition of the Phosphoinositide 3-Kinase Pathway Cancer Res., November 1, 2005; 65(21): 9807 - 9816. [Abstract] [Full Text] [PDF]

				L. J. Donato and N. Noy Suppression of Mammary Carcinoma Growth by Retinoic Acid: Proapoptotic Genes Are Targets for Retinoic Acid Receptor and Cellular Retinoic Acid-Binding Protein II Signaling Cancer Res., September 15, 2005; 65(18): 8193 - 8199. [Abstract] [Full Text] [PDF]